Serum anti-glycan antibodies predict complicated Crohnʼs disease behavior

Rieder, Florian; Schleder, Stephan; Wolf, Alexandra; Dirmeier, Andrea; Strauch, Ulrike; Obermeier, Florian; López, Rocío; Spector, Larissa; Fire, Ella; Yarden, Jennifer; Rogler, Gerhard; Dotan, Nir; Klebl, Frank

doi:10.1002/ibd.21179

Cited by 78 publications

(79 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Seow et al have shown that an increasing number of positive antibodies is associated with early CD onset, fistulating and perianal disease, and increased risk for surgery [12]. These findings were confirmed by Rieder et al who showed that a higher number of anti-glycan antibodies predicts a faster progression toward more severe disease [18]. Anti-GM-CSF antibody also correlates with disease activity and an increased risk of relapses [10].…”

Section: Prediction Of Disease Stratification and Severity In CDmentioning

confidence: 85%

Genetic and Serological Markers in Identifying Unclassified Colitis

Fenech¹,

Schembri²,

Ellul³

et al. 2016

New Insights Into Inflammatory Bowel Disease

View full text Add to dashboard Cite

show abstract

Section: Prediction Of Disease Stratification and Severity In CDmentioning

confidence: 85%

Genetic and Serological Markers in Identifying Unclassified Colitis

Fenech¹,

Schembri²,

Ellul³

et al. 2016

New Insights Into Inflammatory Bowel Disease

View full text Add to dashboard Cite

show abstract

“…[37][38][39][40] These biomarkers predict and are qualitatively and quantitatively associated with an aggressive and complicated course of Crohn's disease, including stricturing and/or penetrating phenotype, both in adult and paediatric patients. 13 However, a recent study showed that none of the anti-glycan antibodies ASCA, AMCA, ACCA, ALCA, anti-L and anti-C correlates with disease phenotype.…”

Section: Antimicrobial Antibodiesmentioning

confidence: 99%

Biomarkers of intestinal fibrosis – one step towards clinical trials for stricturing inflammatory bowel disease

Giuffrida

Pinzani

Corazza

et al. 2016

United European Gastroenterology Journal

View full text Add to dashboard Cite

Intestinal fibrosis, caused by an excessive deposition of extracellular matrix components, and subsequent stricture development are a common complication of inflammatory bowel disease. However, currently there are no biomarkers which reliably predict the risk of developing intestinal strictures or identify early stages of fibrosis prior to clinical symptoms. Candidate biomarkers of intestinal fibrosis, including gene variants (i.e. nucleotide-binding oligomerization domain-2 gene), serum microRNAs (miR-19, miR-29), serum extracellular matrix proteins (i.e. collagen, fibronectin) or enzymes (i.e. tissue inhibitor of matrix metalloproteinase-1), serum growth factors (i.e. basic fibroblast growth factor, YKL-40), serum anti-microbial antibodies (i.e. anti-Saccharomyces cerevisiae) and circulating cells (i.e. fibrocytes) have shown conflicting results on relatively heterogeneous patients' cohorts, and none of them was proven to be strictly specific for fibrostenosis, but rather predictive of a disease disabling course. In this review we critically reassess the diagnostic and prognostic value of serum biomarkers of intestinal fibrosis in inflammatory bowel disease.

show abstract

“…Antibodies specific to N-glycolylneuraminic acid, a glycan generated by non-human cell lines, are reported to comprise up to 0.1-0.2% of circulating IgG in normal humans (37). Antibodies specific to other glycans have been associated with adult and pediatric Crohn's disease progression (38)(39)(40)(41) (Table I).…”

Section: Nature and Characterization Of Pre-existing Reactivity In Admentioning

confidence: 99%

“…Associated with Crohn's disease (39,40) Gal-β-1-3-GalNAc-α GalNAc-α Tumor-associated antigens (41) Several pegylated biologics that have received regulatory approval include PegIntron ™ (pegylated interferon-alpha 2b), Pegasys ™ (pegylated interferon-alpha 2) Neulasta ™ (pegylated granulocyte colony stimulating factor), Mircera ™ (methoxy polyethylene glycol-epoetin beta), and Oncaspar ™ (pegylated L-asparaginase derived from E. coli).…”

Section: Pegylated Biologic Proteinsmentioning

confidence: 99%

Pre-existing Antibody: Biotherapeutic Modality-Based Review

Gorovits

Clements-Egan

Birchler

et al. 2016

AAPS J

View full text Add to dashboard Cite

Abstract. Pre-existing antibodies to biotherapeutic drugs have been detected in drug-naïve subjects for a variety of biotherapeutic modalities. Pre-existing antibodies are immunoglobulins that are either specific or cross-reacting with a protein or glycan epitopes on a biotherapeutic compound. Although the exact cause for pre-existing antibodies is often unknown, environmental exposures to non-human proteins, glycans, and structurally similar products are frequently proposed as factors. Clinical consequences of the pre-existing antibodies vary from an adverse effect on patient safety to no impact at all and remain highly dependent on the biotherapeutic drug modality and therapeutic indication. As such, pre-existing antibodies are viewed as an immunogenicity risk factor requiring a careful evaluation. Herein, the relationships between biotherapeutic modalities to the nature, prevalence, and clinical consequences of pre-existing antibodies are reviewed. Initial evidence for pre-existing antibody is often identified during anti-drug antibody (ADA) assay development. Other interfering factors known to cause false ADA positive signal, including circulating multimeric drug target, rheumatoid factors, and heterophilic antibodies, are discussed.

show abstract

Serum anti-glycan antibodies predict complicated Crohnʼs disease behavior

Abstract: This is the first study showing the clinical value of serum antiglycan antibodies for prediction of a more complicated disease course in adult patients with CD.

Cited by 78 publications

References 24 publications

Genetic and Serological Markers in Identifying Unclassified Colitis

Genetic and Serological Markers in Identifying Unclassified Colitis

Biomarkers of intestinal fibrosis – one step towards clinical trials for stricturing inflammatory bowel disease

Pre-existing Antibody: Biotherapeutic Modality-Based Review

Contact Info

Product

Resources

About